| Name | Title | Contact Details |
|---|
Transform your legal and compliance function by synchronizing regulations with your business. Leverage artificial intelligence to conduct research and apply regulations.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Willow is the digital twin for the built world. Our mission is to empower every person and organization to connect with the built world in a whole new way.
Tours Today - Leases Tomorrow. Rently Self-Guided Tours are the most safe and secure way to tour a home or apartment on your own time.
The most flexible video and audio SDK on the market. Build human connection and experience into your app, uniquely deployed on-premises or in the cloud with unparalleled security. Trusted by companies in the public sector, government, healthcare, banking/financial services, broadcasting, education, conferences, gaming, e-sports, social/dating, collaboration, VR/AR, remote assistance, emergency services, content delivery and many more industries